Bupivacaine hydrochloride - Generic Drug Details

What are the generic drug sources for bupivacaine hydrochloride and what is the scope of freedom to operate?

Bupivacaine hydrochloride is the generic ingredient in thirteen branded drugs marketed by Innocoll Pharms, Aspiro, Civica, Eugia Pharma, Hikma Pharms, Hospira, Meitheal, Onesource Specialty, Somerset, Intl Medicated, Fresenius Kabi Usa, B Braun Medical, Baxter Hlthcare Corp, Huons, Septodont, and Amphastar Pharms Inc, and is included in forty-seven NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupivacaine hydrochloride has eighty-three patent family members in twenty-four countries.

There are six drug master file entries for bupivacaine hydrochloride. Twenty-four suppliers are listed for this compound.

Summary for bupivacaine hydrochloride

International Patents:	83
US Patents:	2
Tradenames:	13
Applicants:	16
NDAs:	47
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	24
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	1,980
What excipients (inactive ingredients) are in bupivacaine hydrochloride?	bupivacaine hydrochloride excipients list
DailyMed Link:	bupivacaine hydrochloride at DailyMed

Recent Clinical Trials for bupivacaine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ganesh M. Shankar	PHASE2
University of Virginia	PHASE4
Wake Forest University Health Sciences	PHASE4

See all bupivacaine hydrochloride clinical trials

Pharmacology for bupivacaine hydrochloride

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

Anatomical Therapeutic Chemical (ATC) Classes for bupivacaine hydrochloride

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for bupivacaine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	SENSORCAINE	bupivacaine hydrochloride	INJECTABLE;SPINAL	071202-001	Apr 15, 1987		DISCN	No	No
Hospira	BUPIVACAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;SPINAL	071810-001	Dec 11, 1987	AP	RX	No	No
Hospira	BUPIVACAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;INJECTION	070590-001	Feb 17, 1987	AP	RX	No	No

International Patents for bupivacaine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Turkey	201907156
San Marino	T201700507
Eurasian Patent Organization	201491278

Market Dynamics and Financial Trajectory for Bupivacaine Hydrochloride

Last updated: July 29, 2025

Introduction

Bupivacaine Hydrochloride is a local anesthetic extensively used in surgical, obstetric, and pain management procedures. Its unique pharmacological profile—offering prolonged anesthesia—has sustained its market relevance. As healthcare systems evolve and new regional anesthesia techniques emerge, understanding the market dynamics and financial prospects for Bupivacaine Hydrochloride is pivotal for stakeholders, including manufacturers, investors, and healthcare providers.

---

Market Overview

The global market for local anesthetics, including Bupivacaine Hydrochloride, is projected to grow steadily over the next decade. Key drivers include increasing surgical procedures, rising prevalence of chronic pain, and technological advancements in minimally invasive interventions. Bupivacaine’s market share is influenced by its efficacy, duration of action, and safety profile compared to alternatives such as lidocaine and ropivacaine.

---

Current Market Size and Growth Drivers

Market Size

As of 2022, the global local anesthetics market was valued at approximately USD 4.1 billion, with Bupivacaine accounting for an estimated 25-30% of this segment (~USD 1 billion). The regional distribution reveals steady growth in North America and Europe, driven by high procedural volumes and regulatory approvals, while emerging markets such as Asia-Pacific show accelerated growth potential due to expanding healthcare infrastructure.

Growth Drivers

• Rising Surgical Volume: The global increase in surgeries—particularly orthopedic, cardiovascular, and obstetric interventions—directly amplifies demand for long-acting local anesthetics like Bupivacaine.
• Chronic Pain Management: An aging population and rising prevalence of chronic pain conditions elevate demand for effective local anesthetics.
• Advancements in Anesthesia Techniques: Improved delivery systems and formulations extend Bupivacaine’s efficacy, attracting both clinicians and patients.
• Regulatory Approvals: Market expansion hinges on regulatory acceptance, with newer formulations (e.g., liposomal Bupivacaine) gaining approval for prolonged analgesia.

---

Market Dynamics

Competitive Landscape

The market features several key players: Mylan (now Viatris), Pf

izer, Hikma Pharmaceuticals, Hikma, and AstraZeneca. These companies offer both generic Bupivacaine hydrochloride and branded variants, including extended-release formulations. Market entry barriers include stringent safety and efficacy standards, but patent expirations and innovative delivery systems are reshaping the competitive landscape.

Regulatory and Patent Environment

Patent expirations for certain formulations have facilitated increased generic competition, exerting downward pressure on prices. Conversely, proprietary formulations like liposomal Bupivacaine ( marketed as Exparel by Pacira BioSciences) command premium pricing due to their extended duration of action.

Supply Chain and Manufacturing Factors

Global manufacturing depends on quality control, regulatory compliance, and supply chain integrity—especially amid geopolitical tensions and pandemics. Disruptions can lead to shortages or price volatility, influencing market dynamics significantly.

Pricing and Reimbursement Policies

Pricing strategies vary globally; high-income countries feature extensive reimbursement frameworks, incentivizing adoption. In contrast, price sensitivity in emerging markets constrains revenue per unit, yet higher procedural volumes compensate for lower prices.

---

Financial Trajectory and Forecast

Revenue Projections

The Bupivacaine Hydrochloride segment is projected to grow at a compound annual growth rate (CAGR) of approximately 4-6% from 2022 to 2032. Drivers include new formulations extending duration of analgesia, increased procedural volumes, and expanding geographic markets.

Innovation and Product Development Impact

The advent of liposomal Bupivacaine has significantly influenced revenue streams, with some formulations reaching commercial sales of USD 200 million annually (as reported by Pacira in 2022). These premium-price products are expected to maintain a strong growth trajectory, contingent upon regulatory approvals and clinical adoption.

Emerging Market Opportunities

Rapid economic expansion in Asia-Pacific, Latin America, and Africa offers emerging revenue streams, driven by healthcare infrastructure investments and growing surgical capacities. Market penetration strategies targeting these regions could propel the financial future of Bupivacaine-based products.

Potential Challenges

• Generics and Price Erosion: Patent expirations threaten margins, compelling innovation and differentiation efforts.
• Regulatory Hurdles: Stringent approval processes and safety concerns can delay or restrict market access for new formulations.
• Supply Chain Disruptions: Raw material shortages or geopolitical issues could impair production and distribution.

---

Strategic Outlook

Leading companies are investing in R&D to develop novel delivery systems—such as sustained-release implants—and expanding formulations to capture diverse clinical needs. Strategic licensing agreements and partnerships are vital for entering emerging markets and gaining regulatory clearances.

Market consolidation could also shape future dynamics, with larger firms acquiring smaller innovators to expand portfolios and global reach.

---

Conclusion

The Bupivacaine Hydrochloride market exhibits a resilient, steadily expanding trajectory supported by clinical demand, technological innovations, and demographic shifts. While competition and pricing pressures persist, premium and extended-release formulations are poised to dominate growth avenues. Stakeholders must monitor regulatory developments, patent landscapes, and evolving clinical practices to optimize financial outcomes.

---

Key Takeaways

• The global market for Bupivacaine Hydrochloride is projected to grow at a CAGR of 4-6% through 2032, buoyed by procedural volume increases and innovation.
• Extended-release formulations, especially liposomal Bupivacaine, drive premium revenues but face regulatory and pricing challenges.
• Patent expirations and generic competition accelerate price erosion, necessitating innovation and differentiation.
• Emerging markets offer substantial revenue opportunities, contingent on tailored commercialization strategies and regulatory navigation.
• Supply chain resilience and favorable reimbursement policies are crucial for sustained growth.

---

FAQs

1. What factors most influence Bupivacaine Hydrochloride’s market growth?
Market growth hinges on rising surgical volumes, innovation in delivery systems, aging populations with chronic pain, and expanding healthcare infrastructure—particularly in emerging economies.

2. How do patent expirations affect the market dynamics for Bupivacaine Hydrochloride?
Patent expirations lead to increased generic competition, exerting downward pressure on prices and margins, prompting brands to innovate with extended-release formulations to maintain market share.

3. What role do advanced formulations like liposomal Bupivacaine play in the industry?
They enable prolonged analgesia, command premium pricing, and are a key driver of revenue growth, especially in high-value surgical settings. Regulatory acceptance is critical for their expansion.

4. How can manufacturers capitalize on emerging markets?
By tailoring marketing strategies, complying with local regulations, and establishing reliable supply chains, manufacturers can penetrate underserved regions with high surgical and pain management needs.

5. What are the main challenges facing the Bupivacaine Hydrochloride market?
Key challenges include intense generic competition, price erosion, regulatory hurdles, safety concerns, and supply chain disruptions affecting production and distribution.

---

Sources

[1] Market Research Future, “Global Local Anesthetics Market Analysis,” 2022
[2] Pacira BioSciences Annual Report, 2022
[3] Allied Market Research, “Liposomal Bupivacaine Market Forecast,” 2022
[4] FDA Pharmaceutical Approvals Database, 2022
[5] IQVIA, “Global Trends in Surgical Procedures and Pain Management,” 2022